Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients

Robert S. Woodward, Mark A. Schnitzler, Jack Baty, Jeffrey A. Lowell, Lissa Lopez-Rocafort, Seema Haider, Thasia G. Woodworth, Daniel C. Brenna

Research output: Contribution to journalArticlepeer-review

332 Scopus citations


This study sought to determine 1) the incidence and costs of new onset diabetes mellitus (NODM) associated with maintenance immunosuppression regimens following renal transplantation and 2) whether the mode of dialysis pretransplant or the type of calcineurin inhibition used for maintenance immunosuppression affected either the incidence or cost of NODM. The study examined the United States Renal Data System's clinical and financial records from 1994 to 1998 of all adult, first, single-organ, renal transplantations in either 1996 or 1997 with adequate financial records. It used the second diagnosis of diabetes in previously nondiabetic patients to identify NODM. While NODM had an incidence of approximately 6% per year among wait-listed dialysis patients, NODM over the first 2 years post-transplant had an incidence of almost 18% and 30% among patients receiving cyclosporine and tacrolimus, respectively. By 2 years post-transplant, Medicare paid an extra $21500 per newly diabetic patient. We estimated the cost of diabetes attributable to maintenance immunosuppression regimens to be $2025 and $3308 for each tacrolimus patient and $1137 and $1611 for each cyclosporine patient at I and 2 years post-transplant, respectively.

Original languageEnglish
Pages (from-to)590-598
Number of pages9
JournalAmerican Journal of Transplantation
Issue number5
StatePublished - May 2003


  • Cost
  • Diabetes
  • Incidence
  • Kidney


Dive into the research topics of 'Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients'. Together they form a unique fingerprint.

Cite this